{
    "id": "dbpedia_8100_2",
    "rank": 48,
    "data": {
        "url": "https://in.marketscreener.com/quote/stock/SIMCERE-PHARMACEUTICAL-GR-119080130/news/Simcere-Pharmaceutical-Group-Limited-and-Mabpharm-Limited-Announce-Approval-on-the-Marketing-of-ENLI-47086558/",
        "read_more_link": "",
        "language": "en",
        "title": "Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China",
        "top_image": "https://in.marketscreener.com/images/twitter_MS_fdnoir.png",
        "meta_img": "https://in.marketscreener.com/images/twitter_MS_fdnoir.png",
        "images": [
            "https://www.facebook.com/tr?id=385171022294487&ev=PageView&noscript=1",
            "https://cdn.zonebourse.com/images/logo_marketscreenerW.svg",
            "https://cdn.zonebourse.com/images/loupe_recherche.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/in.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/us.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/gb.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/ca.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/in.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/de.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/at.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/ch.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/es.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/fr.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/ch.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/it.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/nl.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/be.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/in.png",
            "https://cdn.zonebourse.com/static/instruments-logo-45553945",
            "https://cdn.zonebourse.com/static/instruments-logo-45554109",
            "https://cdn.zonebourse.com/static/instruments-logo-133757270",
            "https://cdn.zonebourse.com/static/instruments-logo-128433627",
            "https://cdn.zonebourse.com/static/instruments-logo-119600672",
            "https://cdn.zonebourse.com/static/instruments-logo-119643024",
            "https://cdn.zonebourse.com/static/instruments-logo-45553945",
            "https://cdn.zonebourse.com/static/instruments-logo-45554109",
            "https://cdn.zonebourse.com/static/instruments-logo-133757270",
            "https://cdn.zonebourse.com/static/instruments-logo-128433627",
            "https://cdn.zonebourse.com/static/instruments-logo-119600672",
            "https://cdn.zonebourse.com/static/instruments-logo-119643024",
            "https://cdn.zonebourse.com/images/png-country/24x24/us.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/gb.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/ca.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/in.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/de.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/at.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/ch.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/es.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/fr.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/ch.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/it.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/nl.png",
            "https://cdn.zonebourse.com/images/png-country/24x24/be.png",
            "https://cdn.zonebourse.com/static/instruments-squared-119080130",
            "https://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=119080130&Type=Intraday&Width=120&Height=45&ShowAxis=0&DTstart=2024-08-16&Render=Line&BottomMargin=3&TopMargin=5&Prev=5.43&TIMEZONE=Europe/Paris",
            "https://cdn.zonebourse.com/images/membre/chart3.png",
            "https://cdn.zonebourse.com/images/membre/chart3.png",
            "https://www.marketscreener.com/zbcache/charts/ObjectChart.aspx?Name=119080130&Type=Custom&Intraday=1&Width={width}&Height={height}&Cycle=DAY1&Duration={duration}&Render=Candle&ShowCopyright=2&ShowName=0&Locale=en&ShowVolume=1&Company=Skin:ZonebourseLight&externload=",
            "https://cdn.zonebourse.com/static/instruments-squared-119080130",
            "https://in.marketscreener.com/images/consensus_flch.gif",
            "https://cdn.zonebourse.com/static/resize/40/40/https://cdn.zonebourse.com/images/services/2023/footer_logoass_portail.png",
            "https://cdn.zonebourse.com/static/resize/40/40/https://cdn.zonebourse.com/images/services/2023/em_logoass_perfhisto.png",
            "https://cdn.zonebourse.com/static/resize/40/40/https://cdn.zonebourse.com/images/services/2023/footer_logoass_2001_en.png",
            "https://cdn.zonebourse.com/static/resize/106/48/https://cdn.zonebourse.com/static/images/footer/img_footer_google_45.png",
            "https://cdn.zonebourse.com/static/resize/106/48/https://cdn.zonebourse.com/static/images/footer/img_footer_trustpilot_4.png",
            "https://cdn.zonebourse.com/static/resize/40/40/https://cdn.zonebourse.com/images/services/2023/footer_logoass_membresl.png",
            "https://cdn.zonebourse.com/static/resize/40/40/https://cdn.zonebourse.com/images/services/2023/footer_logoass_resilitaion.png",
            "https://cdn.zonebourse.com/static/resize/40/40/https://cdn.zonebourse.com/images/services/2023/footer_logoass_experts.png",
            "https://cdn.zonebourse.com/static/images/footer/img_footer_appstore.png",
            "https://cdn.zonebourse.com/static/images/footer/footer_logo_ms.png",
            "https://in.marketscreener.com/images/actions/2020/popup/blockmembernav/x-circle-fill.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Markets"
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2024-06-25T11:44:00+02:00",
        "summary": "",
        "meta_description": "The board of directors of Simcere Pharmaceutical Group Limited announced that, ENLITUO , which is collaborated by theGroup and Mabpharm Limited , has recently been approved for marketing in China by...",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "MarketScreener",
        "canonical_link": "https://in.marketscreener.com/quote/stock/SIMCERE-PHARMACEUTICAL-GR-119080130/news/Simcere-Pharmaceutical-Group-Limited-and-Mabpharm-Limited-Announce-Approval-on-the-Marketing-of-ENLI-47086558/",
        "text": "The board of directors of Simcere Pharmaceutical Group Limited announced that, ENLITUO (cetuximab beta injection), which is collaborated by theGroup and Mabpharm Limited (\"Mabpharm\"), has recently been approved for marketing in China by the National Medical Products Administration of China (the \"NMPA\"), the indication of which is to be used for the first-line therapy of RAS/BRAF wild-type metastatic colorectal cancer (\"mCRC\") in combination with FOLFIRI regimen. ENLITUO (product code: CMAB009) is a recombinant anti-EGFR chimeric monoclonal antibody and is a category 2.4 improved biologics. It is prepared using a specific expression process, effectively avoiding glycosylation modification that may lead to hypersensitivity.\n\nIts safety and efficacy has been confirmed from the results of various completed clinical trials. In March 2023, the drug marketing application of ENLITUO was accepted by the NMPA. On August 18, 2023, the Group entered into a cooperation agreement with Mabpharm, pursuant to which the Group obtained the exclusive commercial rights in respect of ENLITUO in Chinese mainland.\n\nENLITUO is the first anti-epidermal growth factor receptor (\"EGFR\") monoclonal antibody innovative drug developed in China with independent intellectual property rights which has been approved by the NMPA for first-line therapy of mCRC. The successful launch of ENLITUO will provide high quality and affordable biological targeted remedy for Chinese patients with tumor."
    }
}